查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1753910

反义及 RNAi 治疗市场报告（依技术、给药途径、应用及地区）2025 年至 2033 年

Antisense & RNAi Therapeutics Market Report by Technology, Route of Administration, Application, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球反义及RNAi疗法市场规模达18亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到33亿美元，2025-2033年期间的复合年增长率（CAGR）为7.03%。全球遗传疾病和慢性病的日益普及推动了该市场稳步增长，这需要创新疗法、各主要市场支持性监管环境以加快新疗法的审批和商业化，以及药物输送系统的持续技术进步。

反义和 RNAi 治疗市场分析：

  • 主要市场驱动因素：强大的技术驱动因素推动市场的发展，例如药物传递系统的快速进步，这增加了对细胞的治疗影响和靶向特异性，以及遗传疾病和慢性疾病的高发病率，这需要使用尖端的治疗方式。
  • 主要市场趋势：反义和 RNAi 治疗行业的主要趋势之一是其与基于独特基因图谱的个人化医疗紧密相关，旨在改善患者预后。
  • 地理趋势：根据反义和 RNAi 治疗市场分析，北美凭藉其优秀的医疗保健基础设施、高额的医疗保健支出和友善的监管环境，在反义和 RNAi 治疗市场占据主导地位。
  • 竞争格局：这是一个充满活力的市场，汇集了许多传统医药市场参与者，例如顶尖製药公司和成熟的创新企业。竞争格局将取决于对自有技术专利的争夺、获得监管机构的批准以及开展新的合作。
  • 挑战与机会：反义及RNAi疗法市场研究报告显示，该产业面临的主要挑战在于开发和管理RNAi及反义疗法的高成本与复杂性。反义疗法也蕴含着机会，因为它将使该行业成为创新和低成本药物研发的场所，从而在尚未治癒的遗传疾病领域取得突破。

反义和 RNAi 治疗市场趋势：

药物输送系统的技术进步

在这个市场中，主要驱动因素之一是药物输送方法的持续发展。这些技术使RNA分子能够干净且有效率地输送至相关细胞，避免降解，进而提高治疗效果。例如，脂质奈米颗粒和偶联技术使反义寡核苷酸或siRNA的细胞摄取和平衡变得前所未有的微不足道。它提高了输送效率，同时增强了疗法与特定人体物质的相似度，而这些物质对于癌症、疾病和病毒感染等至关重要。反义和RNAi疗法市场预测表明，这些疗法将获得大量的研究关注和资金投入。例如，诺华于2023年7月收购了DTx Pharma，这是一家专注于神经科学领域短干扰RNA疗法的生物技术公司。同样，这些收购也正在创造积极的市场前景。

遗传性疾病和慢性病的盛行率不断上升

群体中遗传性疾病和慢性疾病的发生率不断上升，有力地推动了反义和RNAi疗法市场的成长。亨廷顿氏舞蹈症、某些类型的癌症以及各种遗传性疾病只是少数常见且缺乏有效治疗方法的疾病，这催生了对反义和RNAi疗法的需求。此外，反义和RNAi疗法作为候选致病基因的抑制剂，为疾病的治疗提供了新的途径。一方面，这些新药最有可能应用在临床上。另一方面，由于能够针对特定基因，它们为目前无法透过传统药理学方法治疗的患者提供了一种新的治疗方式。这反过来又催生了对新生物製药研发项目持续投资的明确需求。

支持新疗法的监管环境

反义和RNAi疗法的需求受到有利监管环境的推动。例如，美国食品药物管理局（FDA）孤儿药产品开发办公室于2023年10月宣布，将在2024财年提供资金，用于承担罕见疾病和病症自然史研究的费用。该RFA的既定目标是「提昇科学严谨性，促进合作，造福罕见疾病患者」。此外，FDA和EMA等全球卫生机构正在加快任何新疗法的审查流程，包括RNAi和反义技术。同时，孤儿药资格认定、加速审批和优先审查凭证等监管激励措施也变得更加重要，因为它们将更有动力激励製药公司投入精力开发反义和RNAi疗法。

反义和 RNAi 治疗市场细分：

按技术划分：

  • RNA干扰
    • siRNA
    • miRNA
  • 反义RNA

反义 RNA 占据反义和 RNAi 治疗市场的大部分份额

反义RNA技术凭藉其成熟的方法和悠久的临床应用历史，在反义和RNAi治疗市场中占据领先地位。反义RNA的工作原理是合成RNA分子与特定的mRNA序列结合，进而阻断致病标靶基因。此外，其广泛的应用范围从遗传病理到各种慢性疾病（包括癌症），也奠定了其领先地位。此外，与其他RNAi技术不同，这些领先技术已在长达两年的时间内广泛应用，这使得人们能够投入大量资源用于研究和开发其作用机制和给药方式。此外，一些反义治疗药物已在RNAi技术市场上获得FDA註册，这最终证实了它们的有效性并鼓励了进一步的投资。所有这些因素都有助于确保其在最大市场份额中的稳定发展；此外，在反义子领域，已经提交上市申请的有前景的药物也已上市。因此，这项技术引领着RNA治疗市场，并为该领域的突破奠定了基础。

依给药途径分类：

  • 静脉途径
  • 皮下途径
  • 鞘内途径
  • 肺部输送
  • 腹腔注射
  • 其他的

肺部给药占业界最大份额

在反义和RNAi疗法市场中，肺部给药已成为给药途径的主导。其理由包括直接用于治疗呼吸系统疾病，局部给药可显着提高疗效。因此，能够进入肺部并携带治疗药物，对于治疗呼吸道合胞病毒和肺动脉高压等疾病以及肺癌等疾病都具有显着效果。它能够使溶液在病灶处达到高浓度，减少全身性副作用，从而降低副作用，提高患者依从性并提高整体治疗效果。此外，能够有效地将药物输送至肺部组织的创新吸入器和解决方案也是一个重要方面。由于负荷不断增加，人们面临着尽可能提高治疗有效性和针对性的压力。因此，肺部给药是RNAi技术市场的关键发展重点，并引领整体投资和创新配额。

按应用分类：

  • 肿瘤学
  • 心血管疾病（CVD）
  • 呼吸系统疾病
  • 肾臟疾病
  • 神经退化性疾病
  • 遗传性疾病
  • 传染病
  • 其他的

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美引领市场，占据反义和 RNAi 治疗市场最大份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是反义和RNAi疗法最大的区域市场。

北美是反义和RNAi疗法市场最大的区域。这项优势主要归功于该地区成熟的生物技术和製药研究基础设施。此外，各国政府和其他全球卫生组织提供的空前支持，为反义和RNAi治疗平台发展所需的研究和先进开发创造了有利环境。根据反义和RNAi疗法市场分析，该地区多家领先的生物技术和製药公司的存在，创造了激烈的竞争并促进了创新，加速了开发机会和产品上市。此外，北美积极的监管环境，例如美国食品药物管理局（FDA）的积极参与，已快速审批多种用于治疗多种遗传和慢性疾病的RNA药物，也为RNA疗法市场提供了支持。此外，该地区癌症和遗传性疾病等目标疾病的高发生率也创造了反义和RNAi疗法的需求。因此，北美引领反义和 RNAi 治疗市场，是技术开发的主导者，也是基于 RNA 的治疗产品的主要市场。

竞争格局：

市场研究报告还对市场竞争格局进行了全面分析，并提供了所有主要公司的详细资料。反义和 RNAi 治疗行业的主要市场参与者包括：

  • Alnylam製药公司
  • Arbutus 生物製药公司
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma 有限公司
  • Bio-Path 控股公司
  • Dicerna Pharmaceuticals Inc.（诺和诺德公司）
  • 伊奥尼斯製药公司
  • OliX製药公司
  • Phio製药公司
  • Sarepta治疗公司
  • 沉默治疗公司
  • 圣诺製药公司

市场主要参与者正日益参与研发，以丰富其基因治疗产品组合。他们积极建立策略合作伙伴关係，收购小型生物技术公司，或与学术机构和研发中心合作，以利用新兴颠覆性技术并加速药物开发。同时，考虑到高昂的成本和开发风险，公司在临床试验方面投入了大量资金，以确保其在更广泛的应用组合（尤其是在基因转移性疾病领域）中的有效性和安全性。与监管机构的合作可以提升公司的竞争力，并引导他们更快推出新药。这项措施对于创造竞争优势以及积极的反义和RNAi疗法市场前景至关重要。

本报告回答的关键问题

  • 全球反义和 RNAi 治疗市场有多大
  • 2025 年至 2033 年期间全球反义和 RNAi 治疗市场的预期成长率是多少
  • 推动全球反义和 RNAi 治疗市场的关键因素有哪些
  • COVID-19 对全球反义和 RNAi 治疗市场有何影响
  • 根据技术，全球反义和 RNAi 治疗市场如何划分
  • 根据给药途径，全球反义和 RNAi 治疗市场如何划分
  • 全球反义和 RNAi 治疗市场的主要区域有哪些
  • 全球反义和 RNAi 治疗市场的主要参与者/公司有哪些

本报告回答的关键问题

  • 全球反义和RNAi治疗市场有多大？ 2025-2033年期间，全球反义和RNAi治疗市场的预期成长率是多少？
  • 推动全球反义和 RNAi 治疗市场发展的关键因素有哪些？
  • COVID-19 对全球反义和 RNAi 治疗市场有何影响？
  • 根据技术，全球反义和 RNAi 治疗市场如何分布？
  • 根据给药途径，全球反义和 RNAi 治疗市场如何分布？
  • 全球反义和 RNAi 治疗市场的关键区域有哪些？
  • 全球反义和 RNAi 治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球反义与 RNAi 治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依技术

  • RNA干扰
    • 关键部分
      • siRNA
      • miRNA
  • 反义RNA

第七章：市场区隔：依行政途径

  • 静脉途径
  • 皮下途径
  • 鞘内途径
  • 肺部输送
  • 腹腔注射
  • 其他的

第 8 章：市场区隔：按应用

  • 肿瘤学
  • 心血管疾病（CVD）
  • 呼吸系统疾病
  • 肾臟疾病
  • 神经退化性疾病
  • 遗传性疾病
  • 传染病
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第十章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Alnylam Pharmaceuticals Inc.
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals Inc.
    • Benitec Biopharma Ltd.
    • Bio-Path Holdings Inc.
    • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
    • Ionis Pharmaceuticals Inc.
    • OliX Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Sarepta Therapeutics Inc.
    • Silence Therapeutics
    • Sirnaomics Inc.
Product Code: SR112025A6549

The global antisense & RNAi therapeutics market size reached USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2033, exhibiting a growth rate (CAGR) of 7.03% during 2025-2033. The market is experiencing steady growth driven by the increasing prevalence of genetic and chronic diseases globally necessitates innovative treatments, supportive regulatory environments across major markets to expedite the approval and commercialization of new therapies, and continuous technological advancements in drug delivery systems.

Antisense & RNAi Therapeutics Market Analysis:

  • Major Market Drivers: The market is driven by powerful technological drivers such as rapid advancements in drug delivery systems, which increased therapeutic impact on cells and targeting specificity, and a high incidence of genetic disorders and chronic diseases, which requires the use of cutting-edge therapeutic modalities.
  • Key Market Trends: One of the major antisense & RNAi therapeutics industry trends is its tight association with the personalization of medicine based on unique genetic profiles and aimed at improving patient outcomes.
  • Geographical Trends: According to the antisense & RNAi therapeutics market analysis, North America dominates the market for Antisense & RNAi Therapeutics due to its excellent healthcare infrastructure, high healthcare spending, and friendly regulatory environment.
  • Competitive Landscape: This is a dynamic market with a pool of traditional drug market players such as top pharmaceutical companies and innovators that have established themselves. The competitive space will have to determine the battle for patents of owned technologies, achieving the green light from the regulatory authorities, and making new collaborations.
  • Challenges and Opportunities: The antisense & RNAi therapeutics market research report shows that the industry's major challenge is the high cost and complexity of developing and managing RNAi and antisense-based therapies. The latter is also an opportunity since it will transform the sector into loci of innovation and low-cost drug discovery resulting in breakthroughs in untreated genetic diseases.

Antisense & RNAi Therapeutics Market Trends:

Technological advancements in drug delivery systems

In this market, one of the major drivers is the continuing developments of drug delivery methods. These technologies allow RNA molecules to be delivered to relevant cells cleanly and efficiently, in a pattern that avoids degradation and hence provided enhanced efficacy in terms of therapy. For example, lipid nanoparticles and conjugate technologies enabled the previously negligible cellular uptake and balance of antisense oligonucleotides or siRNA. It increases delivery while enhancing the degree of similarity in which therapeutics are suitable to target specific human material, which is critical in cancer, disorders, and viral infections, among other things. The antisense & RNAi therapeutics market forecast indicates that these treatments will gain substantial research attention and financial investment. For instance, Novartis acquired DTx Pharma in July 2023, which is a biotechnology company concentrating on short-interfering RNA therapy for neuroscience indications. Similarly, these acquisitions are creating a positive market outlook.

Increasing prevalence of genetic disorders and chronic diseases

The accelerating incidences of genetic and chronic diseases among the masses is significantly supporting the antisense & RNAi therapeutics market growth. Huntington's, certain types of cancer, and a wide range of hereditary genetic conditions are just a few examples of prevalent illnesses with few efficient treatments, which create demand for antisense & RNAi therapeutics. Along with this, Antisense and RNAi treatment options provide a new avenue as candidate disease-predisposing genes' repressors. On one hand, the new drugs have the best prospects of being included in clinical practice. On the other - by having the ability to target specific genes, they represent a new treatment modality for patients with conditions that are currently unmanageable using conventional pharmacological methods. This, in turn, generates a clear need for continued investment in new biopharmaceutical R&D projects.

Supportive regulatory environment for novel therapies

The antisense & RNAi therapeutics demand is impelled by the supportive regulatory environment. For instance, in October 2023, The Food and Drug Administration's Office of Orphan Products Development announced the availability of funds for fiscal year (FY) 2024 to help underwrite the costs of conducting natural history studies on rare diseases and conditions. The stated goal of this RFA is "to advance scientific rigor and collaboration for the benefit of patients with rare diseases or conditions." In addition, global health authorities, such as the FDA and EMA, are introducing faster review processes for any new therapies, inclusive of RNAi and antisense technology. Meanwhile, regulatory incentives like orphan drug status, accelerated approval, and priority review vouchers gain even more relevance since they give pharmaceutical companies even more incentive to put effort into the development of antisense and RNAi therapies.

Antisense & RNAi Therapeutics Market Segmentation:

Breakup by Technology:

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

Antisense RNA accounts for the majority of the antisense & RNAi therapeutics market share

Antisense RNA technology is the leader in the Antisense & RNAi Therapeutics market due to its mature methodology and the longest history of clinical application. Antisense RNA acts based on synthetic RNA molecules adhering to specific mRNA sequences, and it results in the blockade of target genes responsible for disease. In addition, the broadest possible range of applications from genetic pathologies to chronic diseases of various origins, including cancer, primarily has ensured its leader position. Apart from this, unlike other RNAi technologies, the leaders have already spent up to two years of widespread use, which allowed the investment of large resources in research and developing mechanisms of action and delivery. Moreover, some antisense therapeutic agents are already on the RNAi technology market with active FDA registration, which ultimately confirms their effectiveness and encourages further investment. All these factors contribute to ensuring a steady drill with the most significant share; even more, promising drugs already filed to proliferation can be observed in the antisense subfield. Thus, this technology leads the RNA based therapeutics market and lays the foundation for breakthroughs in this field.

Breakup by Route of Administration:

  • Intravenous Route
  • Subcutaneous Route
  • Intrathecal Route
  • Pulmonary Delivery
  • Intraperitoneal Injection
  • Others

Pulmonary delivery holds the largest share of the industry

In the Antisense & RNAi therapeutics market, pulmonary delivery has taken the lead in terms of administration channels. There are several justifications, including direct utilization in curing respiratory conditions, in which localized delivery significantly increases the effectiveness. Thus, the ability to access the lungs and carry therapeutic agents is effective in treating diseases such as respiratory syncytial virus and pulmonary arterial hypertension as well as directing to lung cancer. It enabled high concentration of the solution on the site of the disease, limited systemic, hence lower side effects, improved patient adherence, and the overall effectiveness of treatment. Moreover, innovative inhalers and solutions that allow efficient drug delivery to lung tissues are also an important aspect. Due to the increasing load, there is pressure to make therapy as effective and targeted as possible. Therefore, pulmonary delivery serves as a key development focus of the RNAi technology market and directs the overall investment and innovation quotas.

Breakup by Application:

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest antisense & RNAi therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for antisense & RNAi therapeutics.

North America is the largest regional segment in the Antisense & RNAi therapeutics market. This prominence is primarily due to the region's mature biotechnological and pharmaceutical research infrastructure. Additionally, unprecedented support from various national governments and other global health organizations has created a conducive environment for research and the advanced development required to progress antisense and RNAi therapy platforms. According to the antisense & RNAi therapeutics market analysis, the presence of several leading biotech and pharmaceutical companies in the region, which has created fierce competition and promoting innovation, has accelerated development opportunities as well as product launch. Additionally, North America's proactive regulatory environment, the exceptional participation of the FDA, which has fast-tracked many RNA-based drugs for several genetic and chronic disease conditions, supports the RNA based therapeutics market. Moreover, the high prevalence of target diseases, including cancer and genetic disorders, in the region creates antisense & RNAi therapeutics demand. Thus, North America leads the Antisense & RNAi Therapeutics market, as a dominant player in technology development and also as the primary market for RNA-based therapeutic products.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the antisense & RNAi therapeutics industry include:

  • Alnylam Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals Inc.
  • Benitec Biopharma Ltd.
  • Bio-Path Holdings Inc.
  • Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
  • Ionis Pharmaceuticals Inc.
  • OliX Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Sarepta Therapeutics Inc.
  • Silence Therapeutics
  • Sirnaomics Inc.

The major players in the market are increasingly involved in research and development to diversify their genetic therapy portfolios. They are actively engaging in strategic partnerships, taking over small biotech companies, or collaborating with academic institutions and R&D centers to capitalize on emerging and disruptive technologies and fast-track drug development. In confluence with this, considering the high costs and development risks, companies make significant investments in clinical trials to guarantee their effectiveness and safety in a wider applications portfolio, especially in AlNM diseases. Collaboration with the regulatory bodies enhances the companies' competitive performance and guides them along the way to bring new drugs faster. This initiative is vital for creating competitive advantages and a positive antisense & RNAi therapeutics market outlook.

Key Questions Answered in This Report

  • 1.How big is the global antisense & RNAi therapeutics market?
  • 2.What is the expected growth rate of the global antisense & RNAi therapeutics market during 2025-2033?
  • 3.What are the key factors driving the global antisense & RNAi therapeutics market?
  • 4.What has been the impact of COVID-19 on the global antisense & RNAi therapeutics market?
  • 5.What is the breakup of the global antisense & RNAi therapeutics market based on the technology?
  • 6.What is the breakup of the global antisense & RNAi therapeutics market based on the route of administration?
  • 7.What are the key regions in the global antisense & RNAi therapeutics market?
  • 8.Who are the key players/companies in the global antisense & RNAi therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antisense & RNAi Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 RNA Interference
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 siRNA
      • 6.1.2.2 miRNA
    • 6.1.3 Market Forecast
  • 6.2 Antisense RNA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Intravenous Route
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous Route
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intrathecal Route
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pulmonary Delivery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intraperitoneal Injection
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Cardiovascular Diseases (CVDs)
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Respiratory Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Renal Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Neurodegenerative Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Genetic Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Infectious Diseases
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast
  • 8.8 Others
    • 8.8.1 Market Trends
    • 8.8.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alnylam Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arbutus Biopharma Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Arrowhead Pharmaceuticals Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Benitec Biopharma Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bio-Path Holdings Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ionis Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 OliX Pharmaceuticals Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Phio Pharmaceuticals Corp.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Sarepta Therapeutics Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Silence Therapeutics
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Sirnaomics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antisense & RNAi Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Antisense & RNAi Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Antisense & RNAi Therapeutics Market: Breakup by Technology (in %), 2024
  • Figure 5: Global: Antisense & RNAi Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Antisense & RNAi Therapeutics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Antisense & RNAi Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Antisense & RNAi Therapeutics (RNA Interference) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Antisense & RNAi Therapeutics (RNA Interference) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Antisense & RNAi Therapeutics (Antisense RNA) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Antisense & RNAi Therapeutics (Intravenous Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Antisense & RNAi Therapeutics (Subcutaneous Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Antisense & RNAi Therapeutics (Intrathecal Route) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Antisense & RNAi Therapeutics (Pulmonary Delivery) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Antisense & RNAi Therapeutics (Intraperitoneal Injection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Antisense & RNAi Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Antisense & RNAi Therapeutics (Oncology) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Antisense & RNAi Therapeutics (Oncology) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Antisense & RNAi Therapeutics (Cardiovascular Diseases (CVDs)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Antisense & RNAi Therapeutics (Respiratory Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Antisense & RNAi Therapeutics (Renal Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Antisense & RNAi Therapeutics (Neurodegenerative Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Antisense & RNAi Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Antisense & RNAi Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Antisense & RNAi Therapeutics (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Antisense & RNAi Therapeutics (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: North America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: North America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United States: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United States: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Canada: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Canada: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Asia-Pacific: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Asia-Pacific: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: China: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: China: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Japan: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Japan: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: India: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: India: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: South Korea: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: South Korea: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Australia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Australia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Indonesia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Indonesia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Europe: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Europe: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Germany: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Germany: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: France: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: France: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: United Kingdom: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: United Kingdom: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Italy: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Italy: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Spain: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Spain: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Russia: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Russia: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Latin America: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Latin America: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Brazil: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Brazil: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Mexico: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Mexico: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Others: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Others: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Middle East and Africa: Antisense & RNAi Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Middle East and Africa: Antisense & RNAi Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 88: Middle East and Africa: Antisense & RNAi Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Global: Antisense & RNAi Therapeutics Industry: SWOT Analysis
  • Figure 90: Global: Antisense & RNAi Therapeutics Industry: Value Chain Analysis
  • Figure 91: Global: Antisense & RNAi Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antisense & RNAi Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 3: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Antisense & RNAi Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Antisense & RNAi Therapeutics Market: Competitive Structure
  • Table 7: Global: Antisense & RNAi Therapeutics Market: Key Players